As we enter 2026, the greatest crisis facing our societies may not be climate change, war or technological upheaval but a silent, invisible epidemic quietly undermining institutions, communities and ...
– RCT2100 co-administered with ivacaftor will assess the safety and tolerability of inhaled CFTR mRNA therapy over 6 weeks in participants with CF – – U.S. sites now enrolling, with U.K. and EU sites ...
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis – RCT2100 co-administered with ivacaftor will assess ...
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results